Video

Strategies for Using Iron Chelation Therapy

For High-Definition, Click

If a patient has received over 10 transfusions and has a ferritin level of >1000 it may be necessary to institute iron chelation therapy (ICT), believes Azra Raza, MD. Patients on ICT should be monitored every 2 to 3 months until the ferritin level goes below 500. At that time, ICT can be discontinued, with continued ferritin level monitoring every 2 to 3 months, Raza notes. If ferritin once again surpasses 1000, ICT can be reinstituted.

Raza stresses that the treating hematologist must also be convinced of the need for ICT in chronically transfused patients, and must advise their patients of this therapy. These treatments are necessary, since chronic iron overload can be a serious condition, specifically in patients with myelodysplastic syndromes. To simplify the administration of ICT, the FDA approved an oral formulation of deferasirox as a treatment for patients with chronic iron overload on March 30, 2015. The new formulation is a once-daily tablet.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.